

Filed 08/03/2004


1449

09896874

Date Mailed: November 15, 2001

Sheet 1 of 1

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 13615.40USU1	Application Number: 09/896,874
	Applicant: Fang et al.	
	Filing Date: June 29, 2001	Group Art Unit: 1614



RECEIVED  
 NOV 28 2001  
 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SL	5,703,129	12/30/1997	Felsenstein et al.			
SL	5,886,046	3/23/1999	Hirschmann et al.			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
SL	WO 98/38167	9/3/1998	PCT			
SL	WO 96/35414	11/14/1996	PCT			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
SL		Copy of PCT International Search Report dated October 17, 2001				
		Shugo et al., Chemical and Pharmaceutical Bulletin, Vol. 40, No. 2, 1992 XP002178294 - Abstract				
		Raddatz, J. of Med. Chem., Vol. 34, No. 11, 1991, pgs. 3267-3280 XP002178295 - Abstract				
		Nishi et al., Chemistry Letters, 1989, pgs. 1993-1996 XP002178296 - Abstract				
		Harbeson et al., J. of Med. Chem., Vol. 32, No. 6, 1989, pgs. 1378-1392 XP002178297 - Abstract				
		Thaisrivongs et al., J. Med. Chem., Vol. 31, No. 7, 1988, pgs. 1369-1376 XP002178298 - Abstract				
		Nakano et al., Bulletin of the Chemical Society of Japan, Vol. 63, No. 8, 1990, pgs. 2224-2232 XP002178299 - Abstract				
		Kaltenbronn et al., J. Med. Chem., Vol. 33, No. 2, 1990, pgs. 838-845 XP002178300 - Abstract				
		Ping et al., J. Med. Chem., Vol. 39, No. 10, 1996, pgs. 1991-2007 XP002178301 - Abstract				
		Plummer et al., Bioorganic & Medicinal Chemistry Letters, Vol. 9, No. 6, 1999, pgs. 835-840 XP002178302 - Abstract				

RECEIVED

AUG 21 2002

TECH CENTER 1600/2900

EXAMINER	S. F. J. J. J.	DATE CONSIDERED	3/31/03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation and not considered. Include copy of this form for next communication to the Applicant.			



\*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fang et al.  
 Serial No.: 09/896,974  
 Filed: June 29, 2001  
 Notice of Allow. Date:

Examiner: unknown  
 Group Art Unit: 1614  
 Docket: 13615.40USU1  
 Batch No.:

Due Date: 11/17/01

Title: COMPOUNDS TO TREAT ALZHEIMER'S DISEASE



TECH CENTER 1600/2900

AUG 28 2001

RECEIVED

1614

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence and the paper(s), as described herein, are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: IDS, Commissioner for Patents, Washington, D.C. 20231, on November 15, 2001.

By: Karen Olsen  
 Karen Olsen

IDS  
 Commissioner for Patents  
 Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Supplemental Information Disclosure Statement, Form 1449, 13 Reference(s), Copy of International Search Report
- ☒ Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers or any future reply, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.  
 P.O. Box 2903, Minneapolis, MN 55402-0903  
 612.332.5300

By: Anna M. Nelson  
 Name: Anna M. Nelson  
 Reg. No.: 48,935  
 AMN:ko



RECEIVED

AUG 21 2002

TECH CENTER 1600/2900